We show that adding rhIL-7-hyFc to CAR T cells improves T cell expansion, persistence, and anti-tumor activity, both with human CAR T cells targeting CD19 or CD33 in an NSG xenograft model and with murine CAR T cells targeting CD19 in two different strains of immunocompetent mice. Here, CD33 is linked to neoplasm.